Using FAPI PET/MRI to Evaluate Prostate Cancer

Description

The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.

Conditions

Prostate Cancer Metastatic Disease, Prostate Cancers

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.

Novel FAP-targeted Approach to Metastatic Prostate Cancer

Using FAPI PET/MRI to Evaluate Prostate Cancer

Condition
Prostate Cancer Metastatic Disease
Intervention / Treatment

-

Contacts and Locations

Madison

University of Wisconsin, Madison, Wisconsin, United States, 53705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or older
  • * Able and willing to provide informed consent
  • * Known diagnosis of prostate cancer with established or suspected non-osseous, non-nodal metastases
  • * Scheduled for standard-of-care PSMA PET
  • * Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases
  • * Willing and able to undergo PET/MRI as part of this research
  • * Unable or unwilling to provide informed consent
  • * Contraindication(s) to or inability to undergo PET/MRI
  • * Participants for whom PET/MRI will delay timely delivery of treatment
  • * Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
  • * Have their own prescription for the medication
  • * The informed consent process is conducted prior to the self-administration of this medication
  • * Come to the research visit with a driver

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Ali Pirasteh, MD, PRINCIPAL_INVESTIGATOR, University of Wisconsin, Madison

Study Record Dates

2026-10